Print

Cannabis Science Inc. Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development  
6/5/2012 11:00:25 AM

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (CBIS.OB) announced today the initiation of a research program to explore the commercial development of Phytocannabinoid-based therapeutics for drug resistant HIV infection. The program will facilitate an antiviral investigation of Phytocannabinoids inhibition of HIV TAT. Cannabis Science is a publicly traded, pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges.
//-->